ClinicalTrials.gg
RecruitingNCT07273838Updated Mar 13, 2026

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

A Phase 2 interventional study of Dapagliflozin 10mg Tab and Placebo in Heart Failure and Acute Kidney Injury, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Planned enrollment
21st of 59
130 · median 100
Started
2026
with 2 others
Phase 2
9 of 59
4 open now
Primary completion
2028-08
later than 14 of 18 live
Registered
55th of 59
by date

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 21st largest by planned enrollment, is one of 3 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 14 of the 18 other live ones, and was the 55th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious. Investigators will assess if SGLT2 inhibition improves a composite cardio-renal outcome (mortality, dialysis, AKI progression, decongestion metrics, heart failure symptoms). Secondary objectives of this study are to compare individual components of the composite outcome as well as changes in biomarkers of kidney injury, inflammation, repair and oxidative stress between those exposed to the SGLT2 inhibitor vs placebo.

Read the detailed description

Individuals with heart failure are prone to acute kidney injury (AKI) as well as fluctuations in creatinine that meet AKI criteria. AKI diagnosis often complicates heart failure management and leads to interruptions of medications with long term benefit. AKI is also associated with long-term complications such as chronic kidney function and cardiovascular mortality. There is no efficient universal treatment for this type of AKI. In acute heart failure (AHF), although loop diuretics are the mainstay of treatment, diuretic resistance complicates the management. A drug that improves diuretic efficiency may lead to faster decongestion and improvement in kidney function.

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are drugs consistently shown to reduce hospitalizations in heart failure as well as progression of chronic kidney disease. They have also shown to promote kidney tubular health in pre-clinical models of kidney injury. They have been included in the armamentarium of heart failure care as goal directed medical therapy (GDMT) but concerns of efficacy and safety in patients with kidney dysfunction continue to limit their uptake and maintenance.

This study aims to promote increased use of SGLT2 inhibitors by demonstrating their safety and possible benefit in patients who develop kidney injury in the setting of heart failure to avoid interruptions in GDMT use.

To this end, 130 hospitalized adults with acute cardiorenal syndrome will be enrolled into a randomized controlled trial. Subjects will be randomized to receive either dapagliflozin or placebo for 14 days or until discharge (whichever comes first). Blood and urine samples will be collected for biomarker analysis, symptom and adverse event surveys will be administered, and various clinical parameters will be recorded on up to 6 study visits during hospitalization.

The primary outcome is a composite of short- and intermediate-term cardiorenal outcomes including: heart failure specific outcomes (objective measures of decongestion (i.e., effective diuresis), and a patient-reported outcome incorporating two dimensions of health state and a visual analogue scale (VAS)), kidney-specific outcomes (dialysis receipt, AKI progression to a higher stage, and change in serum creatinine), length of stay, and mortality. Secondary outcomes include trends in biomarkers of kidney injury, inflammation, oxidative stress, and repair, as well as individual components of the primary outcome as well as re-hospitalization rates.

03

Conditions studied

  • Heart Failure
  • Acute Kidney Injury

Keywords

  • Acute cardiorenal syndrome
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥ 18 and ≤ 85 years-old
  • Diagnosed with heart failure of either preserved or reduced left ventricular function
  • Have signs of heart failure exacerbation
  • Ability to take an oral medication
  • Willing to adhere to the SGLT2i vs placebo regimen

Exclusion criteria

Exclusion Criteria:

  • AKI can be primarily explained by another etiology
  • Current use of SGLT2 inhibitor or exposure in the past 72 hours
  • Pregnancy or lactation (pregnancy test prior to enrollment in women of child-bearing age)
  • Known allergic reactions to components of an SGLT2 inhibitor
  • Treatment with another drug for heart failure different from or in addition to usual care within the 72 hours preceding AKI
  • Any individual who meets any of the following criteria will be excluded from participation in this study:
  • Documented history of ileal conduit (neobladder)
  • No means of collecting urine such as patients with documented incontinence without indwelling or external urinary catheter
  • Advanced kidney disease at baseline defined as baseline \< 25 ml/min/1.73m2
  • Unexplained hypoglycemia in the past 30 days from enrollment
  • History of Fournier's gangrene (pelvic necrotizing fasciitis)
  • History of recurrent urinary tract infection (UTI): defined as documented UTI at least 2x in the preceding 6 months or 3 x in the preceding 12 months
  • End-stage kidney disease with dialysis requirement
  • Oliguria: defined as less than 30 ml urine output per hour for more than two consecutive hours or less than 500 ml over the preceding 24 hours
  • Severe acute kidney injury with indications for dialysis
  • Current dialysis receipt for acute kidney injury
  • Comfort measures only
  • Solid organ transplant on
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    SGLT2i

    Subjects receive once daily 10 mg of oral dapagliflozin (Farxiga) for 14 days (or until discharge). Empaglifolozin may be used in case of dapagliflozin shortage.

    Drug: Dapagliflozin 10mg Tab

  • Placebo comparator
    Placebo

    Subjects receive once daily administration of a placebo comparator for 14 days (or until discharge).

    Drug: Placebo

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administration of 10mg oral dapagliflozin once daily for 14 days (or until discharge).

  • DrugPlacebo

    Administration of placebo comparator once daily for 14 days (or until discharge).

06

What researchers measure

Primary outcomes

  1. Cardio-renal clinical improvement calculated as a Win Ratio

    This outcome is assessed using a win ratio (total wins in the intervention group divided by total wins in the control group). Pairwise comparisons of predetermined components are made between each participant in the intervention and control group hierarchically in order of clinical importance, with a "win" assigned to the participant with the more favorable result at the first level of difference. The win ratio is the number of "winning" pairs for the treatment group divided by the number of "losing" pairs, with a win ratio greater than 1 indicating a benefit for the treatment.

    Time frame: Calculated at 30 days post-randomization

Secondary outcomes

  1. Change in slope of serum creatinine over 14 days from enrollment

    Measure of kidney function; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  2. Change in slope of serum cystatin-C over 14 days from enrollment

    Measure of kidney function; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  3. Change in slope of serum serum NT-proBNP over 14 days from enrollment

    Measure of kidney function; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  4. Change in slope of blood kidney injury molecule-1 (KIM-1) over 14 days from enrollment

    Biomarker of renal tubular injury; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  5. Change in slope of urine kidney injury molecule-1 (KIM-1) over 14 days from enrollment

    Biomarker of renal tubular injury; assessed as a change in urine concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  6. Change in slope of blood neutrophil gelatinase-associated lipocalin (NGAL) over 14 days from enrollment

    Biomarker of renal tubular injury; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  7. Change in slope of urine neutrophil gelatinase-associated lipocalin (NGAL) over 14 days from enrollment

    Biomarker of renal tubular injury; assessed as a change in urine concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  8. Change in slope of blood interleukin-6 (IL-6) over 14 days from enrollment

    Biomarker of inflammation; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  9. Change in slope of urine interleukin-6 (IL-6) over 14 days from enrollment

    Biomarker of inflammation; assessed as a change in urine concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  10. Change in slope of blood interluekin-18 (IL-18) over 14 days from enrollment

    Biomarker of inflammation; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  11. Change in slope of urine interluekin-18 (IL-18) over 14 days from enrollment

    Biomarker of inflammation; assessed as a change inurine concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  12. Change in slope of blood MPO over 14 days from enrollment

    Biomarker of oxidative stress; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  13. Change in slope of urine MPO over 14 days from enrollment

    Biomarker of oxidative stress; assessed as a change in urine concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  14. Change in slope of blood uromodulin (UMOD) over 14 days from enrollment

    Biomarker of repair; assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  15. Change in slope of urine uromodulin (UMOD) over 14 days from enrollment

    Biomarker of repair; assessed as a change in urine concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  16. Change in slope of blood chitinase-3-like protein 1 (YKL-40) over 14 days from enrollment

    Biomarker of repair. Assessed as a change in blood concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  17. Change in slope of urine chitinase-3-like protein 1 (YKL-40) over 14 days from enrollment

    Biomarker of repair. Assessed as a change in urine concentration.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 +/- 4 days

  18. Change in slope of urine volume over 5 days from enrollment

    Measure of decongestion; measured daily (i.e. every 24 hours) according to floor protocol.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4 post-enrollment

  19. Change in slope of weight over 14 days from enrollment

    Measure of decongestion; assessed upon physical exam.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4 and 14 post-enrollment

  20. Change in slope of breathlessness score over 14 days from enrollment

    Measure of decongestion using a survey, scored on a Likert scale from 1-5 (5 indicates more severe breathlessness).

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment

  21. Change in slope of edema grade over 14 days from enrollment

    Measure of decongestion; a score from 0 to 4+ is given on physical examination, with a higher score indicating higher edema.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment

  22. Change in slope of patient-reported edema over 14 days from enrollment

    Measure of decongestion using a survey, scored on a Likert scale from 1-5 (5 indicates more severe edema).

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment

  23. Change in slope of patient-reported VAS dyspnea score over 14 days from enrollment

    A patient reported outcome measured on a visual analog scale of 1-100mm, with 100 indicating worse breathlessness.

    Time frame: Measured at the time of enrollment (day 0) and on days 1-4, and day 14 post-enrollment

  24. Cumulative Lasix equivalent diuretic dose over 5 days

    Measure of decongestion

    Time frame: Up to 5 days from enrollment

  25. Proportion with kidney injury progression

    Proportion with dialysis receipt or AKI progression to a higher stage up to 14 days from enrollment

    Time frame: Up to 14 days post-enrollment

  26. Percent survival at 30 days post-enrollment

    Percent of subject's surviving to 30 days post-enrollment

    Time frame: Up to 30 days post-enrollment

  27. Percent of subjects re-hospitalized with heart failure and AKI at 30 days post-enrollment

    Percent of rehospitalization up to 30 days post-enrollment

    Time frame: Up to 30 days post-enrollment

  28. Proportion with prescription of SGLT2i

    Proportion with prescription of SGLT2i by subject's own provider

    Time frame: Up to 30 days post-enrollment

  29. Incidence of adverse events during exposure

    Number of adverse events experienced by subjects, including sodium or potassium derangements, metabolic acidosis, urinary tract infections, fungal genitourinary infection, hypotension, allergic reactions, and hypoglycemia

    Time frame: Up to 14 days post-enrollment or until hospital discharge

  30. Change in heart failure symptoms (mobility and self care)

    Change in score using a full and modified version of the EQ-5D-5L-VAS. The full questionnaire contains 5 dimensions of state of health and the VAS (visual analog scale) addressing perceived overall health and will be conducted on day 0 and 14. The modified version contains two dimensions of health (self care and mobility) and the VAS scale, and will be conducted on days 1, 2, 3, and 4. The EQ-5D-5L dimensions are scored on a Likert Scale from 1-5, with 5 indicating worsening health. The VAS is scored on a scale of 1 to 100, with 100 indicating better perceived overall health.

    Time frame: Measured on Days 0, 1, 2, 3, 4, and 14 post-enrollment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data for the primary and secondary outcomes will be made available.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Upon publication; indefinitely.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2028, 29 months after the start.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Dec 10, 2025
StartActual
Mar 5, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Oct 31, 2029
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07273838
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Mar 5, 2026
Primary completion
Aug 31, 2028 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Mar 13, 2026

Study contacts

Abinet Aklilu, MD
Contact
abinet.aklilu@yale.edu
203-931-5064
Francis Wilson
Contact
francis.p.wilson@yale.edu
Abinet Aklilu, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion